Kikuchi-Fujimoto Disease in Pediatrics

Autor: Erna Kristiani, Selina Natalia, Elizabeth Victoria Fedora Ritonga, Stanislaus Djokomuljanto, Erick Fransisco Kan

Publikováno v: Journal of Pediatric Surgery Case Reports, Vol 73, Iss , Pp 101989- (2021)

Background: Kikuchi-Fujimoto Disease (KFD)11 KFD: Kikuchi-Fujimoto Disease. is a rare, benign, idiopathic, and self-limiting lymphadenitis typically affecting head and neck regions. It was first reported in 1972 in Japan, and seldomly reported in chi

Externí odkaz: https://doaj.org/article/1a61e5df8aa2431eb8f60d97af8133d8

Neuroendoscopic aspiration and lavage of intraventricular empyema following shunt infection in infants

Autor: Steven Tandean, Lutfi Hendriansyah, Stanislaus Djokomuljanto, Nico Adi Saputra, Andry Juliansen, Silvia Valentina, Monica Ann Mulry, Julius July

Publikováno v: The Pan African Medical Journal, Vol 31, Iss 15 (2018)

Bacterial ventriculitis is one of the most common and serious complications of shunt placement. Shunt infection has varied management and is difficult to treat neurosurgically. We report a case of intraventricular empyema due to shunt infection. Stan

Externí odkaz: https://doaj.org/article/02d21f246bfc44208a5da217c61863f3

No developmental toxicity observed with dolutegravir in rat whole embryo culture.

Autor: Posobiec LM; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Chapman SP; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Murzyn SF; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Rendemonti JE; Department of Reproductive Toxicology, GlaxoSmithKline USA, Collegeville, Pennsylvania, USA., Stanislaus DJ; Department of Safety Assessment, GlaxoSmithKline USA, Philadelphia, Pennsylvania, USA., Romach EH; ViiV Healthcare US, Research Triangle Park, North Carolina, USA.

Publikováno v: Birth defects research [Birth Defects Res] 2021 Oct 01; Vol. 113 (16), pp. 1190-1197. Date of Electronic Publication: 2021 Aug 28.

Absence of developmental and reproductive toxicity in animals exposed to dolutegravir.

Autor: Stanislaus DJ; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Posobiec LM; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Laffan SB; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Solomon HM; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Ziejewski MK; Reproductive Toxicology, In Vitro/In Vivo Translation, GlaxoSmithKline, Upper Providence, Pennsylvania., Romach EH; Non-Clinical Safety, Research & Development, Viiv Healthcare, Research Triangle Park, North Carolina.

Publikováno v: Birth defects research [Birth Defects Res] 2020 Feb 01; Vol. 112 (3), pp. 245-261. Date of Electronic Publication: 2019 Dec 20.

Comparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects.

Autor: Theunissen PT; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.; b Medicines Evaluation Board , Utrecht , The Netherlands.; c Innovative Testing in Life Sciences and Chemistry, University of Applied Sciences Utrecht (HU) , Utrecht , The Netherlands., Beken S; d Federal Agency for Medicines and Health Products , Brussels , Belgium., Beyer BK; e Sanofi U.S. Inc. Bridgewater , NJ , USA., Breslin WJ; f Lilly Research Laboratories , Lilly Corporate Center , Indianapolis , IN , USA., Cappon GD; g Pfizer Worldwide Research & Development , Groton , CT , USA., Chen CL; h ILSI-Health and Environmental Sciences Institute , Washington , DC , USA., Chmielewski G; i Covance Laboratories Inc , Greenfield , IN , USA., De Schaepdrijver L; j Janssen R&D, Preclinical Development & Safety Beerse , Belgium., Enright B; k AbbVie Inc , North Chicago , IL , USA., Foreman JE; l ExxonMobil Biomedical Sciences, Inc , Annandale , NJ , USA., Harrouk W; m U.S. Food & Drug Administration , Silver Spring , MD , USA., Hew KW; n Takeda Pharmaceutical Company , Deerfield , IL , USA., Hoberman AM; o Charles-River Laboratories, Preclinical Services , Horsham , PA , USA., Hui JY; p Celgene Corporation , Summit , NJ , USA., Knudsen TB; q U.S. Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park , NC , USA., Laffan SB; r Safety Assessment, GlaxoSmithKline , King of Prussia , PA , USA., Makris SL; s U.S. Environmental Protection Agency, National Center for Environmental Assessment , Washington , DC , USA., Martin M; q U.S. Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park , NC , USA., McNerney ME; t Drug Safety Evaluation, Bristol-Myers Squibb , New Brunswick , NJ , USA., Siezen CL; b Medicines Evaluation Board , Utrecht , The Netherlands., Stanislaus DJ; r Safety Assessment, GlaxoSmithKline , King of Prussia , PA , USA., Stewart J; u Drug Safety & Metabolism, AstraZeneca , Macclesfield , UK., Thompson KE; t Drug Safety Evaluation, Bristol-Myers Squibb , New Brunswick , NJ , USA., Tornesi B; k AbbVie Inc , North Chicago , IL , USA., Van der Laan JW; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.; b Medicines Evaluation Board , Utrecht , The Netherlands., Weinbauer GF; v Covance Preclinical Services GmbH , Muenster , Germany., Wood S; w Merck Research Laboratories , Upper Gwynedd , Pennsylvania , USA., Piersma AH; a Centre for Health Protection, National Institute for Public Health and the Environment (RIVM) , Bilthoven , The Netherlands.; x Institute for Risk Assessment Sciences, Faculty of Veterinary Sciences , Utrecht University , Utrecht , The Netherlands.

Publikováno v: Critical reviews in toxicology [Crit Rev Toxicol] 2016 Nov; Vol. 46 (10), pp. 900-910. Date of Electronic Publication: 2016 Oct 19.